분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-10-17 17:57:12 , Hit : 3001
 Roche hepatitis C drug appears safe in combination

HONG KONG | Thu Oct 14, 2010 7:01pm EDT

HONG KONG Oct 15 (Reuters) - Two experimental drugs -- one of them belonging to Switzerland's Roche (ROG.VX) -- appear to be safe and well-tolerated by hepatitis C patients when used in combination, researchers reported on Friday.

The search for new treatments for hepatitis C has gained urgency because the present cocktail -- interferon and ribavirin -- has serious side effects and a growing number of people do not respond to interferon anymore.

In a paper published in The Lancet, researchers in Australia, New Zealand and the United States said patients who were given the two experimental drugs -- danoprevir and Roche's RG7128 -- appeared to tolerate the combination well.

A total of 88 patients in Australia and New Zealand participated in the 13-day phase 1 trial, of whom 14 were given placebo, or drugs with no therapeutic effect.

The rest were divided into seven groups and given both drugs in different dosages.

Patients who were given the highest doses -- 1,000 milligrams of RG7128 and 900 mg of danoprevir twice daily -- showed huge reductions in viral loads by day 13.

"Our study was to combine two different drugs with two different mechanisms of action; they target different parts of the virus," said professor Edward Gane of Auckland City Hospital and Auckland District Health Board in New Zealand.

"We wanted to see if we can prevent emergence of resistance and suppress the virus and this is certainly what was shown. There were no cases of resistance in this study."

Viral loads for several of the patients given the highest doses fell to below detection levels, they said in the paper.

Gane said neither drug should be used in isolation because of the speed at which this virus mutates.

"When you use these drugs by themselves, even though they are very well tolerated and have very little side effect, the virus rapidly mutates and becomes resistant to them," he said.

The patients complained of headache, lethargy, rash, gastrointestinal disorders and nausea but they were mild to moderate, the researchers said.

Worldwide, more than 170 million people are infected with the hepatitis C, a disease that can result in liver cirrhosis, or hardening, and finally liver cancer. (Reporting by Tan Ee Lyn; Editing by Sugita Katyal)








807   First Clinical Trial of Gene Therapy for Muscular Dystrophy Lends Insight Into the Disease  이성욱 2010/10/11 2568
806   Hepatitis C virus infection linked to fat enzyme in liver cells  이성욱 2010/10/14 3215
805   Hepatitis C Virus Infection Linked to Fat Enzyme in Liver Cells  이성욱 2010/10/15 2978
  Roche hepatitis C drug appears safe in combination  이성욱 2010/10/17 3001
803   헤르페스 감염 메커니즘 밝혀져  이성욱 2010/10/17 5890
802   Study points to possible gene therapy for depression  이성욱 2010/10/22 2500
801   More than a chicken, fewer than a grape - Exact tally of human genes remains elusive  이성욱 2010/10/25 2565
800   Strides Against Hepatitis C Open Door to Blockbusters  이성욱 2010/11/02 2572
799   Black patients fare well on Vertex hepatitis C drug  이성욱 2010/11/02 2715
798   Too Much SP2 Protein Turns Stem Cells Into “Evil Twin” Tumor-forming Cancer Cells  관리자 2010/11/02 3895
797   NC State Develops More Precise Genetic ‘Off Switches’  이성욱 2010/11/03 2636
796   Breakthrough in cancer vaccine research  이성욱 2010/11/08 2690
795   DNA sequence may be lost in translation  이성욱 2010/11/10 2789
794   Lung Cancer in Smokers, Nonsmokers May Be a Different Disease  이성욱 2010/11/10 2579
793   Why brain tumors hard to treat  이성욱 2010/11/23 2923
792   Vertex submits application for hepatitis C drug  이성욱 2010/11/25 3432
791   Tumours grow their own blood vessels  이성욱 2010/11/25 2363
790   Top 5 papers of 2010  이성욱 2010/12/10 2332
789   Microbe gets toxic response  이성욱 2010/12/10 2471
788   Basel Declaration defends animal research  이성욱 2010/12/10 2373

[이전 10개] [1]..[21][22][23] 24 [25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN